Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by P. K. Epling-Burnette
A Critical Role for Phosphatase Haplodeficiency in the Selective Suppression of Deletion 5q MDS by Lenalidomide
Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
Related publications
Lenalidomide With or Without Erythropoietin in Transfusion-Dependent Erythropoiesis-Stimulating Agent-Refractory Lower-Risk MDS Without 5q Deletion
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Unusual Clonal Evolution Involving 5q in a Case of Myelodysplastic Syndrome With Deletion 5q 31 Treated With Lenalidomide
Haematologica
Hematology
Extended Survival and Reduced Risk of AML Progression in Erythroid-Responsive Lenalidomide-Treated Patients With Lower-Risk Del(5q) MDS
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Cryptic 5q Deletion in a Patient With Myelodysplastic Syndrome
British Journal of Haematology
Hematology
Diagnosis of Del(5q) MDS, 14 Years After JAK-2 Positive PV Appearance: Complete Remission of Both Diseases With Lenalidomide Monotherapy
Mediterranean Journal of Hematology and Infectious Diseases
Infectious Diseases
Hematology
The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-Del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
Deletion 5q in Myelodysplastic Syndrome: A Paradigm for the Study of Hemizygous Deletions in Cancer
Leukemia
Cancer Research
Oncology
Anesthesiology
Pain Medicine
Hematology
Lenalidomide in 5q Minus Myelodysplastic Syndrome: How Long Is Enough?
Annals of Hematology
Medicine
Hematology
Megakaryocytes Harbour the Del(5q) Abnormality Despite Complete Clinical and Cytogenetic Remission Induced by Lenalidomide Treatment
British Journal of Haematology
Hematology
